As such, in combination with monoclonal antibodies such as Elotuzumab targeting the glycoprotein SLAM family member 7 (SLAMF7), also known as CS1 (52, 53) or Daratumumab and Isatuximab targeting the CD38, IMiDs have showed significant synergistic effects, increase in overall response rate (ORR) and extension of progression-free survival (PFS) and overall survival (OS) in MM patients (54–56). This evidence concerns the gene CD38 and Miyoshi myopathy.